These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 37247901)

  • 1. Novel α-Trifluoromethyl Chalcone Exerts Antitumor Effects Against Prostate Cancer Cells.
    Shimada T; Naito R; Toriumi R; Nakagawa R; Aoyama S; Kamijima T; Kano H; Kadomoto S; Iwamoto H; Yaegashi H; Izumi K; Kadono Y; Nakata H; Saito Y; Nakagawa-Goto K; Mizokami A
    Anticancer Res; 2023 Jun; 43(6):2433-2444. PubMed ID: 37247901
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A new flavonoid derivative exerts antitumor effects against androgen-sensitive to cabazitaxel-resistant prostate cancer cells.
    Naito R; Kano H; Shimada T; Makino T; Kadomoto S; Iwamoto H; Yaegashi H; Izumi K; Kadono Y; Nakata H; Saito Y; Goto M; Nakagawa-Goto K; Mizokami A
    Prostate; 2021 Apr; 81(5):295-306. PubMed ID: 33493355
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CCL2 induces resistance to the antiproliferative effect of cabazitaxel in prostate cancer cells.
    Natsagdorj A; Izumi K; Hiratsuka K; Machioka K; Iwamoto H; Naito R; Makino T; Kadomoto S; Shigehara K; Kadono Y; Lin WJ; Maolake A; Mizokami A
    Cancer Sci; 2019 Jan; 110(1):279-288. PubMed ID: 30426599
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neoisoliquiritin exerts tumor suppressive effects on prostate cancer by repressing androgen receptor activity.
    Chen C; Shao R; Li B; Zhai Y; Wang T; Li X; Miao L; Huang J; Liu R; Liu E; Zhu Y; Gao X; Zhang H; Wang Y
    Phytomedicine; 2021 May; 85():153514. PubMed ID: 33676083
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Marked response to cabazitaxel in prostate cancer xenografts expressing androgen receptor variant 7 and reversion of acquired resistance by anti-androgens.
    Ylitalo EB; Thysell E; Thellenberg-Karlsson C; Lundholm M; Widmark A; Bergh A; Josefsson A; Brattsand M; Wikström P
    Prostate; 2020 Feb; 80(2):214-224. PubMed ID: 31799745
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The CCL2-CCR2 Axis Contributes to Migration of Cabazitaxel-resistant Prostate Cancer Cells.
    Natsagdorj A; Izumi K; Hiratsuka K; Naito R; Kadomoto S; Iwamoto H; Yaegashi H; Shigehara K; Nakata H; Mizokami A
    Anticancer Res; 2023 Jun; 43(6):2561-2569. PubMed ID: 37247914
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of an anabolic selective androgen receptor modulator that actively induces death of androgen-independent prostate cancer cells.
    Schmidt A; Meissner RS; Gentile MA; Chisamore MJ; Opas EE; Scafonas A; Cusick TE; Gambone C; Pennypacker B; Hodor P; Perkins JJ; Bai C; Ferraro D; Bettoun DJ; Wilkinson HA; Alves SE; Flores O; Ray WJ
    J Steroid Biochem Mol Biol; 2014 Sep; 143():29-39. PubMed ID: 24565564
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 5'-Chloro-2,2'-dihydroxychalcone and related flavanoids as treatments for prostate cancer.
    Saito Y; Mizokami A; Tsurimoto H; Izumi K; Goto M; Nakagawa-Goto K
    Eur J Med Chem; 2018 Sep; 157():1143-1152. PubMed ID: 30189396
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sulforaphane increases the efficacy of anti-androgens by rapidly decreasing androgen receptor levels in prostate cancer cells.
    Khurana N; Talwar S; Chandra PK; Sharma P; Abdel-Mageed AB; Mondal D; Sikka SC
    Int J Oncol; 2016 Oct; 49(4):1609-19. PubMed ID: 27499349
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Crosstalk Between Androgen-sensitive and Androgen-insensitive Prostate Cancer Cells.
    Takezawa Y; Izumi K; Machioka K; Iwamoto H; Naito R; Makino T; Kadomoto S; Natsagdorj A; Kadono Y; Keller ET; Zhang J; Mizokami A
    Anticancer Res; 2018 Apr; 38(4):2045-2055. PubMed ID: 29599322
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Androgens modify therapeutic response to cabazitaxel in models of advanced prostate cancer.
    Begemann D; Wang Y; Yang W; Kyprianou N
    Prostate; 2020 Sep; 80(12):926-937. PubMed ID: 32542812
    [TBL] [Abstract][Full Text] [Related]  

  • 12. α-Trifluoromethyl Chalcones as Potent Anticancer Agents for Androgen Receptor-Independent Prostate Cancer.
    Saito Y; Mizokami A; Izumi K; Naito R; Goto M; Nakagawa-Goto K
    Molecules; 2021 May; 26(9):. PubMed ID: 34068627
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of the effects of androgenic Chinese herbal medicines on androgen receptors and tumor growth in experimental prostate cancer models.
    Zhang ZB; Ip SP; Cho WC; Hu Z; Huang YF; Luo DD; Xian YF; Lin ZX
    J Ethnopharmacol; 2020 Oct; 260():113058. PubMed ID: 32525068
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prostate fibroblasts enhance androgen receptor splice variant 7 expression in prostate cancer cells.
    Sasaki T; Yoshikawa Y; Kageyama T; Sugino Y; Kato M; Masui S; Nishikawa K; Inoue T
    Prostate; 2023 Mar; 83(4):364-375. PubMed ID: 36479717
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Exploitation of the Androgen Receptor to Overcome Taxane Resistance in Advanced Prostate Cancer.
    Martin SK; Kyprianou N
    Adv Cancer Res; 2015; 127():123-58. PubMed ID: 26093899
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Benzyldihydroxyoctenone, a novel nonsteroidal antiandrogen, shows differential apoptotic induction in prostate cancer cells in response to their androgen responsiveness.
    Suh H; Oh HL; Lee CH
    J Microbiol Biotechnol; 2011 May; 21(5):540-4. PubMed ID: 21617354
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The adrenal androgen androstenediol is present in prostate cancer tissue after androgen deprivation therapy and activates mutated androgen receptor.
    Mizokami A; Koh E; Fujita H; Maeda Y; Egawa M; Koshida K; Honma S; Keller ET; Namiki M
    Cancer Res; 2004 Jan; 64(2):765-71. PubMed ID: 14744796
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The andean anticancer herbal product BIRM causes destabilization of androgen receptor and induces caspase-8 mediated-apoptosis in prostate cancer.
    Shamaladevi N; Araki S; Lyn DA; Ayyathurai R; Gao J; Lokeshwar VB; Navarrete H; Lokeshwar BL
    Oncotarget; 2016 Dec; 7(51):84201-84213. PubMed ID: 27705939
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of the androgen receptor as a novel mechanism of taxol chemotherapy in prostate cancer.
    Gan L; Chen S; Wang Y; Watahiki A; Bohrer L; Sun Z; Wang Y; Huang H
    Cancer Res; 2009 Nov; 69(21):8386-94. PubMed ID: 19826044
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Repression of cell proliferation and androgen receptor activity in prostate cancer cells by 2'-hydroxyflavanone.
    Ofude M; Mizokami A; Kumaki M; Izumi K; Konaka H; Kadono Y; Kitagawa Y; Shin M; Zhang J; Keller ET; Namiki M
    Anticancer Res; 2013 Oct; 33(10):4453-61. PubMed ID: 24123015
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.